Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

NCT#:

NCT QR Code

Title:

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Protocol:

NRG-BR003

Cancer Type:

Breast

Study Sponsor:

NCI / ECOG-ACRIN

Brief Summary:

This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.

Study Type:

Interventional

Date Opened at SVMHS:

28-Jan-2016

Recruitment Status:

Closed

Study Population:

Eligibility Criteria:

The tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination

Principal Investigator:

Hong Zhao, MD, Oncology, SVMC Cancer Care, (831) 755-1701

Participating Institution:

Salinas Valley Memorial Healthcare System & Salinas Valley Medical Clinics & Salinas Valley Memorial Hospital

SVMHS Clinical Research Program:

Terri Nielsen, MSJ, RN, CCRP, Clinical Research Program Manager, [email protected]

Link to ClinicalTrials.gov:

https://clinicaltrials.gov/ct2/show/record/NCT02488967?term=NRG-BR003&draw=2&rank=1